Humana Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humana Inc. - HUM

Humana’s outlook is deteriorating, with profits plunging and legal risks mounting.

What the company is saying

Humana Inc. is presenting a narrative of transparency around its recent financial struggles, emphasizing that it is disclosing key metrics and forward-looking expectations. The company wants investors to believe it is being forthright about the challenges it faces, particularly the sharp increase in its benefits expense ratio and the resulting impact on profitability. The specific claims highlighted include a benefits expense ratio of approximately 91.4% for Q4 2023 and 88% for the full year, a 2023 adjusted EPS of $26.09 per share (over $2 below its own November 2023 guidance), and a projected 2024 adjusted EPS of only $16 per share—$10 less than 2023 and far below the $29 per share analysts expected. The announcement is blunt about these negative developments, but it buries or omits any discussion of revenue, cash flow, operational initiatives, or management’s plan to address the cost pressures. There is no commentary from management, no forward-looking optimism, and no attempt to reframe the disappointing results in a positive light. The tone is factual and negative, with a communication style that is more defensive than proactive, likely shaped by the concurrent securities class action lawsuit and ongoing investigation by Kahn Swick & Foti, LLC. Notably, the only individuals named are Charles C. Foti, Jr., a former Attorney General of Louisiana and partner at KSF, and Lewis Kahn, KSF’s Managing Partner—both representing the law firm investigating Humana, not the company itself. Their involvement signals the seriousness of the legal scrutiny but does not reflect any institutional support for Humana. This narrative fits into a crisis management mode rather than a typical investor relations strategy, with the company forced to acknowledge negative realities rather than shape a positive investment thesis. Compared to prior communications (which are not available for direct comparison), the messaging here is unusually stark and devoid of the usual corporate optimism.

What the data suggests

The disclosed numbers paint a clear picture of financial deterioration at Humana. The benefits expense ratio, a key measure of how much of premium income is spent on claims, rose to 91.4% in Q4 2023 and 88% for the full year—both increases, indicating that medical costs are consuming a larger share of revenue. Adjusted EPS for 2023 came in at $26.09 per share, which is more than $2 per share below what the company itself predicted just two months earlier in November 2023. This shortfall signals either a rapid deterioration in business fundamentals or a significant forecasting error. For 2024, the company expects adjusted EPS to fall further to $16 per share, a dramatic $10 per share drop from 2023 and well below the $29 per share analysts had forecast. This guidance implies that the cost pressures are not a one-off event but are expected to persist throughout the coming year. The company also disclosed a loss for Q4 2023, but did not provide the specific loss figure, nor did it offer any detail on revenue, net income, or cash flow. The lack of granularity and omission of key financial metrics makes it difficult to fully assess the company’s operational health or to pinpoint the drivers of the negative trends. An independent analyst, looking only at the numbers, would conclude that Humana is facing a significant and ongoing profitability crisis, with little evidence of a turnaround in the near term. The gap between what is claimed and what is evidenced is minimal—if anything, the numbers are worse than the narrative, as the company is forced to acknowledge both realised and expected underperformance.

Analysis

The announcement is factual and negative in tone, focusing on Humana Inc.'s deteriorating financial performance and ongoing legal issues. Most claims are realised and supported by disclosed numerical data, such as the increased benefits expense ratio and lower-than-expected adjusted EPS for 2023. The only forward-looking statements concern the expectation of continued high medical costs and a further drop in 2024 EPS, both of which are presented as management guidance rather than promotional targets. There is no evidence of exaggerated or inflated language; the narrative is proportionate to the disclosed results and does not attempt to frame disappointing outcomes in a positive light. No large capital outlay or long-dated, uncertain returns are discussed. The gap between narrative and evidence is minimal, with the announcement providing a direct account of realised financial setbacks and ongoing litigation.

Risk flags

• ●Operational risk is high, as the benefits expense ratio has risen sharply to 91.4% in Q4 2023 and 88% for the full year, indicating that medical costs are outpacing premium growth. This erodes profitability and suggests that cost controls or pricing power are insufficient.
• ●Financial risk is acute, with adjusted EPS for 2023 coming in at $26.09 per share—over $2 below the company’s own recent guidance—and 2024 guidance slashed to $16 per share, a $10 drop year-over-year. This signals a rapid and material decline in earnings power.
• ●Disclosure risk is present, as the company omits key financial metrics such as revenue, net income, cash flow, and the specific Q4 2023 loss figure. The lack of detail impedes a full assessment of financial health and may mask further weaknesses.
• ●Legal risk is material, with Humana and certain executives facing a securities class action lawsuit for alleged failure to disclose material information. The court has allowed the case to proceed, increasing the risk of costly settlements or adverse findings.
• ●Pattern-based risk is evident in the company’s recent failure to meet its own guidance, with 2023 EPS falling short by more than $2 per share just two months after the last forecast. This undermines management’s credibility and raises concerns about forecasting accuracy.
• ●Timeline/execution risk is high, as the company expects elevated medical costs to persist for all of 2024 but provides no plan or timeline for remediation. Investors face the risk that negative trends will continue or worsen before any turnaround is possible.
• ●Forward-looking risk is significant, as the majority of the company’s claims about 2024 are negative projections rather than realised results. If cost pressures are underestimated or new headwinds emerge, actual performance could be even worse than forecast.
• ●Geographic and institutional risk is low in this context, as the only notable individuals named are from the law firm investigating Humana, not from the company or major institutional investors. Their involvement signals legal seriousness but does not imply any operational or financial support for Humana.

Bottom line

For investors, this announcement signals a clear and immediate deterioration in Humana’s financial outlook, with profitability under severe pressure and no turnaround plan in sight. The company’s own numbers show that it missed its 2023 EPS guidance by a wide margin and expects 2024 to be even worse, with adjusted EPS guidance slashed to $16 per share—far below both last year’s results and analyst expectations. The absence of any discussion of revenue, cash flow, or operational initiatives means there is no evidence that management has a credible strategy to address the rising expense ratio or restore earnings. The ongoing securities class action lawsuit and investigation by Kahn Swick & Foti, LLC add a layer of legal risk and distraction for management, with the court’s decision to let the case proceed suggesting that the allegations are not easily dismissed. The involvement of notable legal figures from KSF underscores the seriousness of the legal scrutiny but does not provide any comfort to investors regarding Humana’s operational or financial prospects. To change this assessment, the company would need to disclose concrete actions to address cost pressures, provide detailed financials, and demonstrate progress toward stabilizing or improving profitability. Key metrics to watch in the next reporting period include the benefits expense ratio, adjusted EPS, and any new disclosures about cost management or legal developments. Given the weight of the evidence, this is a signal to monitor closely rather than act on immediately—there is no positive catalyst, and the risk of further downside is high. The single most important takeaway is that Humana is in a period of acute financial and legal stress, and investors should demand clear evidence of a turnaround before considering new or additional exposure.

Announcement summary

(NYSE:HUM) Humana Inc. announced its financial results for the fourth quarter and full year 2023, disclosing that its benefits expense ratio increased to approximately 91.4% for the fourth quarter of 2023 and approximately 88% for the full year 2023. The company reported 2023 adjusted EPS of only $26.09 per share, or more than $2 per share less than what the Company had predicted in November 2023. On January 25, 2024, the Company further disclosed a loss for the fourth quarter of 2023 and expected that higher level of medical costs would persist for all of 2024, resulting in expected 2024 adjusted EPS of only $16 per share, a $10 per share decrease from 2023, well below analysts' expectations of $29 per share. The Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information during the Class Period in violation of federal securities laws. The Court presiding over the case denied the Company's motion to dismiss the case in part, allowing the case to move forward. Kahn Swick & Foti, LLC continues its investigation into Humana Inc. and is focusing on whether Humana's officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws. KSF has offices in New York, Delaware, California, Louisiana, Chicago, New Jersey, and a representative office in Luxembourg.

Disagree with this article?